Director, Team Lead, Computational Pathology Biomarker Development (Oncology/BioPharmaceuticals) (m/f/d)
Do you thrive at the intersection of AI innovation and clinical translation? Do you have expertise in, and a passion for leading cross functional teams to drive innovation? Would you like to apply your expertise to impact the Oncology and/or BioPharma strategic vision in a company that follows the science and turns ideas into life changing medicines? Then AstraZeneca might be the one for you! In this position you will work with a multi-disciplinary team to pioneer AI-enabled computational pathology and multi-modal biomarkers that fundamentally change how we approach patient selection and drug development, aiming to improve clinical. You will have the opportunity to impact an industry-leading portfolio of diverse therapeutic programs from inception through to life cycle management for marketed drugs. This role is based at our Munch, Germany office.
AstraZeneca is a global, science-led, patient-focused biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines for some of the world’s most serious diseases. But we’re more than one of the world’s leading pharmaceutical companies. SITE DESCRIPTION - Munich, Germany At Computational Pathology Munich (CPM), we make a significant contribution to high-performance, data-driven research and development. Our team operates in a demanding, fast-paced environment where excellent collaboration, clear communication and precise organization are critical. BUSINESS AREA AstraZeneca's Enterprise AI organization is building the future of drug development, a fully integrated AI engine that connects data, technology, and expertise to accelerate breakthroughs across our portfolio. Within AI for Computational Pathology and Biomarkers, we're pioneering AI-powered solutions that transform patient selection, biomarker development, and clinical decision-making at enterprise scale. We thrive on collaboration: actively leveraging capabilities across the organization, promoting reuse, and scaling innovations from concept to global impact. Our measure of success isn't just innovation—it's adoption, scale, and tangible results across therapeutic areas and geographies.